Josh Jennings, an analyst from TD Cowen, reiterated the Buy rating on Cerus. The associated price target remains the same with $5.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Josh Jennings has given his Buy rating due to a combination of factors that point to sustained growth and improving profitability. Cerus delivered fourth-quarter product revenue that matched its earlier pre-announcement and surpassed prior guidance, and management reaffirmed stronger-than-expected 2026 revenue targets, prompting upward revisions to long-term sales forecasts across both worldwide platelet and U.S. IFC franchises.
While tariff and inflation headwinds led to modestly lower 2026–2028 gross margin assumptions, Jennings expects these to be more than offset by better operating leverage, including reduced R&D spending as BARDA-related work winds down and incremental efficiency from the BCA partnership. He also highlights that the stock’s pullback has compressed the valuation to roughly half its five-year average EV-to-2026 sales multiple, which he believes undervalues the company’s momentum, the potential of the U.S. IFC kit-based transition, and the anticipated boost in platelet and IFC adoption via the BCA network, all of which support a Buy recommendation.
According to TipRanks, Jennings is a 3-star analyst with an average return of 2.5% and a 45.29% success rate. Jennings covers the Healthcare sector, focusing on stocks such as Boston Scientific, TransMedics Group, and Abbott Laboratories.